Ustekinumab‑Aekn Suppliers & Bulk Manufacturers
Available Forms: Subcutaneous injection (pre-filled syringes, pens); Intravenous Infusion
Available Strengths: Intravenous Infusion(130 mg/26 mL), Subcutaneous injection (pre-filled syringes, pens)
Reference Brands: Stelara(US & EU); Selarsdi- biosimilar of Stelara
Category: Biosimilars
Selardi, a biosimilar of Stelara (ustekinumab), acts by inhibiting interleukins 12 and 23, reducing inflammation. It effectively treats psoriasis, psoriatic arthritis, and Crohn's disease. Benefits include comparable efficacy, lower cost, and supporting long-term disease management, increasing broad patient access when used under medical supervision.
Product Description:
Selardi, a biosimilar of Stelara (ustekinumab), is regulated in the EU and US, supported by dossiers demonstrating biosimilarity, safety, efficacy, and manufacturing quality in compliance with GMP, EMA, and FDA standards. In the US, FDA approval involves comprehensive clinical validation and safety data. In the EU, CE marking certifies conformity with MDR standards. These biosimilars undergo validation, stability testing, and audits, supported by detailed documentation including biosimilarity, clinical trial data, safety profiles, and manufacturing practices. For licensing procedures, approved dossiers, and the latest regulatory updates, visit Pharmatradz. Ensuring compliance guarantees access to high-quality biosimilar therapies supporting affordable treatment for psoriasis, psoriatic arthritis, and Crohn’s disease worldwide.
Ustekinumab‑Aekn — third party manufacturing & bulk supply
Ustekinumab‑Aekn is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Ustekinumab‑Aekn listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Ustekinumab‑Aekn →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Ustekinumab-aekn is used to treat moderate to severe plaque psoriasis, active psoriatic arthritis, Crohn’s disease, and ulcerative colitis in adults. It helps reduce inflammation by targeting and inhibiting specific proteins in the immune system that cause inflammatory responses.
Ustekinumab-aekn is a human monoclonal antibody produced using recombinant DNA technology in a mammalian cell line. It is a biosimilar to Ustekinumab, designed to closely match the structure, efficacy, and safety of the original biologic product.
The trade name for Ustekinumab-aekn is Wezlana.
Ustekinumab-aekn (Wezlana) is manufactured by Amgen Inc.
The generic name of this product is Ustekinumab-aekn.
The brand name of Ustekinumab-aekn is Wezlana.
Ustekinumab-aekn (Wezlana) is manufactured by Amgen in the United States, with additional production and packaging facilities in Europe for global distribution.
Related Products
Insulin‑Aspart‑Szjj
Strength:
100 units/mL
Form: SQ Injection
Reference Brands: NovoLog; Merilog is biosimilar to NovoLog.
View Details
Eculizumab‑Aeeb
Strength:
300 mg/20 mL (IV infusion),
Form: Injection for intravenous infusion
Reference Brands: Soliris, Bkemv- Biosimilar of Soliris, Epysqli- Biosimilar of Soliris
View Details
Omalizumab‑Igec
Strength:
75 mg/0.5 mL and 150 mg/mL
Form: Pre filled syringe
Reference Brands: Xolair, Omlyclo - a Biosimilar to Xolair
View Details
Tocilizumab-Bavi
Strength:
80 mg/4ml
Form: Intravenous infusion
Reference Brands: Actemra; Tofidence - biosimilar to Actemra (tocilizumab).
View DetailsQuick Response Guaranteed | Verified Suppliers
